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ABSTRACT   
 
Aim 
Metformin is the most widely used oral hypoglycaemic drug, but it may lower B12 status, 
which could have important clinical implications.  We undertook a systematic review and 
meta-analysis of the relationship between metformin use and vitamin B12 deficiency in 
persons with Type 2 Diabetes. 
 
Methods 
Electronic database searches were undertaken (1st January 1957 - 1st July 2013) using the 
Cochrane library, Scopus, CINAHL, Grey literature databases, Pub Med Central,  NICE 
Clinical Guidelines UK, and ongoing clinical trials.  Included studies were of any study 
design, with data from patients with Type 2 Diabetes of any age or gender, taking any dose or 
duration of metformin.  Planned primary outcomes were serum vitamin B12 levels, % 
prevalence or incidence of vitamin B12 deficiency and risk of vitamin B12 deficiency.   
 
 
Results 
Twenty-six papers were included in the review.  10 out of 17 observational studies showed 
statistically significantly lower levels of vitamin B12 in patients on metformin than not on 
metformin. Meta-analysis performed on four trials demonstrated a statistically significant 
overall mean B12 reducing effect of metformin of 57 pmol/L (WMD (fixed)= -0.57 (95% CI: 
-35 to -79 pmol/L) after 6 weeks to 3 months of use. 
 
 
 
  
Conclusion 
The evidence from this review demonstrates an association between metformin usage and 
lower levels of vitamin B12 by 57pmol/L, which leads to frank deficiency or borderline status 
in some patients with Type 2 Diabetes. This suggests it is prudent to monitor B12 levels in 
these patients who are at increased risk of deficiency. 
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1.0 INTRODUCTION  
 
The worldwide prevalence of Diabetes Mellitus is rising.  For western countries, it is  
currently projected that there will be a 17% increase in persons with Diabetes in France and 
Belgium by 2035 [1], with a 22% increase in both the USA and United Kingdom, a 31% 
increase in Canada, and a 3% to 37% increase in other European Union countries [1].  
 
The most widely used class of drugs in persons with Type 2 Diabetes are the biguanides (e.g. 
metformin) which increase insulin sensitivity, and contribute to weight loss [2]. However, 
one of the side effects of metformin is to reduce vitamin B12 status.  Vitamin B12 deficiency is 
under diagnosed and undertreated [3, 4]. Severe deficiency (e.g. pernicious anaemia) can 
result in macrocytic anaemia, peripheral neuropathy and mental-psychiatric changes. Also, 
milder symptoms such as weakness, tiredness, and memory loss can occur before frank 
anaemia [5-7].   
 
Metformin-related vitamin B12 deficiency has been known for over 40 years. However, a 
systematic analysis of the data concerning B12 status and metformin usage has not been 
carried out to date specifically in patients with Type 2 Diabetes. Two recent meta-analyses 
[8, 9] have shown a reduction in B12 levels in populations with metformin use but both used a 
mixed population of patient types (e.g. diabetes, polycystic ovary syndrome, 
hyperlipidaemia).  Therefore, their results may differ from that of patients specifically with a 
diagnosis of Diabetes mellitus and a systematic review and meta-analysis is now required in 
this specific patient group.   
 
  
Our objective was to perform the first systematic review and meta-analysis of the published 
literature (observational and intervention studies) on the association between metformin use 
and vitamin B12 deficiency (as measured by serum vitamin B12) in patients with Diabetes 
mellitus and to consider the potential implications for practice.  
 
  
  
2.0 METHOD  
 
2.1 Literature search 
 
As recommended by the Cochrane Database of Systematic Reviews 
(http://www.cochranelibrary.com/); electronic, hand, web and reference list searches were 
made of the literature to date. Core health bibliographic databases were searched from 1st 
January 1957 (year of the first metformin clinical trial) to 1st July 2013.  These databases 
included the Cochrane library, national, regional and subject specific databases, Scopus, 
CINAHL, Index to theses, Grey literature databases, Conference abstract databases, Pub Med 
Central, Zetoc, NICE Clinical Guidelines UK, ongoing trials and other electronic databases 
(e.g. Nexis). No ethical approval was required for this review as only analysis of already 
published data were used.  
 
The full search strategy for each database is available in the online supplementary material 
(eSearches). A combination of Medical Subject Heading (MeSH) and free-text terms were 
used. The exact search phrases were: “(diabetics OR Diabetes OR Type 1 OR Type 2 OR 
insulin dependent diabetics OR non-insulin dependent diabetics OR insulin dependent 
Diabetes OR non- insulin dependent Diabetes OR non insulin dependent diabetics OR non- 
insulin dependent Diabetes OR IDDM OR NIDDM) AND (metformin OR metformin 
hydrochloride OR biguanides OR biguanide) AND (B12 OR B12 deficiency OR Vitamin B12 
OR Vitamin B12 deficiency OR cobalamin OR cyanocobalamin OR cobalamin deficiency OR 
cyanocobalamin deficiency OR hydroxycobalamin OR hydroxocobalamin OR 
  
hydroxycobalamin deficiency OR hydroxocobalamin deficiency)”.  Reference lists from the 
search results were checked for relevant papers and experts in the field and study authors 
were contacted to enquire about additional published or unpublished studies, ongoing trials 
and background data.  
 
2.2 Eligibility criteria for inclusion and data extraction 
All human studies of cross sectional, cohort or intervention (metformin vs. placebo or other 
control) design published in the English language from the 1st January 1957 to 1st July 2013 
were assessed. Studies reporting data from all patients of any age or gender with Diabetes 
mellitus and taking metformin were considered for inclusion.  No papers were found 
assessing patients with Type 1 Diabetes so the review subsequently focussed only on patients 
with Type 2 Diabetes. Intervention studies were included in the systematic review and meta-
analysis if they assessed oral metformin in patients with Diabetes vs. placebo (or no 
intervention, i.e. comparison with background data for the population). Due to the anticipated 
small number of intervention studies in this subject area we did not plan to carry out any 
subgroup analyses. Data presented in conference abstract form was not included in the 
analysis. 
 
2.3 Primary and secondary outcomes 
The primary outcomes were serum vitamin B12 levels, % prevalence or incidence of vitamin 
B12 deficiency and odds or risk of vitamin B12 deficiency. Diagnosis of vitamin B12 deficiency 
was based upon a serum vitamin B12 level below 150 pmol/l, with borderline deficiency 
between 150-220 pmol/l. In this paper all B12 measurements reported are that of serum 
vitamin B12 (pmol/L), unless otherwise stated.  Secondary outcomes eligible for inclusion 
included reported symptoms, active B12 (Holotranscobalamin II; HoloTC), homocysteine 
  
(Hcy), methylmalonic acid (MMA), haemoglobin (Hb), mean cell volume (MCV), estimates 
of economic costs, and quality of life data.  Due to lack of data on these secondary outcomes 
only the primary outcomes were included in the text of the systematic review and in the 
meta-analysis. 
 
2.4 Statistical analysis 
For cross-sectional surveys, mean ± standard deviation (SD) and correlation coefficients (r) 
were obtained where available. Relative risk (RR), odds ratios (OR) or hazard ratios (HR) 
were extracted for case-control studies, and mean and standard deviations extracted for 
intervention studies.  The number of participants (n) as well as P values and 95% confidence 
intervals for effect estimates were extracted for all study types. Multivariate adjusted analyses 
were used where possible to reduce the effects of confounding.  
 
Review manager (RevMan5.2, Cochrane Collaboration)[10] was used to perform the meta-
analysis and for observational studies multivariate adjusted data used where possible to 
reduce the effects of confounding.  All estimates are presented as mean ± standard deviation 
unless otherwise stated. The Jadad scale and CONSORT statement were used to assess the 
quality of the design and conduct of the randomised controlled trials (RCT’s) [11-13]. The 
international GRADE working group grading system was used to link the quality of the 
evidence into recommendations [14, 15]. 
 
  
3.0 RESULTS  
 
The 26 databases identified 7257 records from which 25 studies were included in this review. 
Figure 1, based on the PRISMA statement (http://www.prisma-statement.org/) illustrates the 
results and the process of screening and selection. The online supplement contains full results 
of searches (Appendix A; Table A.1-A.3), with details of reasons for exclusions of specific 
papers (Appendix B: Table B.1-B.2).  
 
3.1 Systematic Review 
 
Of the 25 papers included in the systematic review, the majority showed significantly lower 
vitamin B12 levels in those patients on metformin. There was only a small amount of data 
on clinical outcomes (e.g. neurological impairment [16], megaloblastic anaemia, 
homocysteine) and functional markers of B12 status. Indeed, most clinical outcomes 
were featured in case reports only (not included in this analysis due to poor 
generalizability of data for n=1 case studies).  
 
For observational studies, the lack of study data, between study differences and concerns 
over small sample sizes prevented pooling of data to assess overall effect size. One study had 
both cross-sectional and cohort data [17] so is mentioned twice. 
 
The 17 cross-sectional studies (Table 1) indicated either an association of metformin use 
with a lower B12 concentration (10 studies [17-26]) or showed no association (7 studies [27-
33]). In terms of cohort-based or retrospective case control studies, 4 studies were included in 
  
the review (Table 2) showing a reduction in HoloTC and total vitamin B12 [17] or increased 
odds of B12 deficiency after 3 years (adjusted OR=2.39 (95% CI 1.46 to 3.91) [34] in 
metformin users, compared with non-users. A nested case-control study[35] identified a 
statistically significant reduction in vitamin B12 deficiency in patients with Type 2 Diabetes 
with peripheral neuropathy, after 6 months of metformin usage. However, one retrospective 
case control study of patient notes [36] found no statistically significant difference between 
the incidences of vitamin B12 deficiency in patients with Diabetes who were using 
metformin compared with those not using metformin [36]. 
 
Characteristics of the intervention studies, including Jadad scores are shown in Table 3. Five 
intervention studies were identified [37-41] of which only two were double blinded, 
randomised and placebo controlled [37, 40].  The Hyperinsulinemia: the Outcome of its 
Metabolic Effects (HOME) trial was a prospective multi-centred RCT [37, 40]. This trial had 
a three phase process including a pre-randomisation measurement in the first 12 weeks, a 
post-randomisation measurement up to 16 weeks and a long-term post-randomisation phase 
measurement up to 4 years. At the 16-week phase there was a statistically significant fall in 
vitamin B12 levels of -14 % (95% CI -4.2 % vs. -24 %) in the metformin group relative to 
placebo (P<0.0001) [37] which dropped further to -19% (95% CI -24% to -14%) (P<0.001) 
by the end of the trial at 4 years [40]. There was a 7.2 % (95% CI 2.3 to 12.1) higher absolute 
risk of B12 deficiency (<150 pmol/L) in the metformin group compared to placebo (P=0.004) 
and the corresponding number needed to harm (NNH) was 13.8 per 4.3 years (95% CI 43.5 to 
8.3)[40]. Importantly, this study reported a treatment by time interaction, with vitamin B12 
concentrations being more extensively lowered with a longer duration of metformin use 
[40]. 
 
  
 
 
3.2 Meta-analysis 
 
Four studies [38, 39, 41] [37] were suitable for inclusion in the meta-analysis. Three trials 
were of short duration [38, 39, 41] (≤4 months) and as the HOME trial data were present in 
two papers (interim analysis at 4 months [37] and final analysis at 4 years [40]), the HOME 
trial 4 months measurement [37] was chosen for the meta-analysis rather than the 4 year 
measurement [40]. This was chosen in order for the HOME trial to be homogenous with 
the other trials in the meta-analysis.  Due to the potential for significant study 
heterogeneity a meta-analysis was conducted using both fixed and random effects models.  
The I2 statistic was used to assess heterogeneity between study outcomes. 
 
Figure 2 summarises the meta-analysis with 95 % confidence intervals indicating statistical 
significance at both individual study levels for Bauman et al (2000) [39] and Wulffele et al 
(2003) [37] and for the overall effect estimate (WMD (fixed)= -57.1 (95% CI -35.5 to -78.8) P< 
0.001 I2=72%). The wide confidence intervals in some studies provide a cautionary note on 
interpretation. The mean difference in serum B12 levels suggests that taking metformin for 6 
weeks to 3 months leads to a statistically significant reduction in B12 concentration by 57 
pmol/L. There was significant heterogeneity, with I2=72%.  
 
A sensitivity analysis, with removal of each study in turn, showed a WMD (fixed) estimate of -
44.6 (95% CI -67.7 to -21.46, P=0.0002, I2=0%) (Bauman et al, 2000[39]), -56.7 (95% CI -
78.6 to -35.0, P<0.00001, I2=81%) (Leung et al, 2010[41]), -71.1 (95% CI -97.1 to -45.1, 
P<0.00001, I2=72%) (Sahin et al, 2007[38]) and -60.1 (95% CI -93.5 to -28.4, P=0.0002, 
  
I2=81%) (Wulffele et al, 2003 [37] ). Therefore the removal of the largest study [37] only had 
a small influence on the effect size estimate, albeit with wider 95% confidence intervals and 
slightly increased heterogeneity.  Conducting the meta-analysis of the four studies with a 
random effects model also led to a statistically significant effect, but with a slightly larger 
effect size and wider 95% confidence intervals (WMD (random)=  -70.1 (95% CI -120.5, -19.7), 
P=0.006, I2=72%). 
  
4.0 DISCUSSION   
 
Observational data in this review has shown lower B12 levels, and an increased risk of 
borderline or frank B12 deficiency with metformin use. Most intervention trials in this review 
were only of short duration (up to 4-months) but indicated a statistically significant reduction 
in B12 levels beyond the 6-weeks period and in some cases led to frank deficiency.   Our fixed 
effects meta-analysis of four intervention trials showed a statistically significant lowering of 
vitamin B12 levels by 57 pmol/L(95% CI: -35 to -79).  
 
This reduction in B12 levels could be clinically significant in causing frank deficiency 
(<150pmol/L) or a borderline status (150-220 pmol/l) in some patients who are in the range 
of 207-277 pmol/L before metformin treatment. Indeed,  20% of men and 27% of women  
(19-64 years old) in the UK National Diet and Nutrition Survey (2004) [42] had a serum B12 
concentration of <200pmol/L [42].  Accordingly, the EPIC (European Prospective 
Investigation into Nutrition and Cancer) cohort in Europe has shown that 5% of adults (<60 
years old) have a B12 concentration of <175pmol/L [43, 44].  According to the effect size 
found in our meta-analysis, it would be predicted that a significant proportion of the patients 
with Type 2 Diabetes in European populations are in danger of developing frank B12 
deficiency or at least borderline levels of deficiency during the first four months of metformin 
treatment.   
 
In terms of previous research, our results supports the recent meta-analysis by Niafar et al. 
(2015) which found a reduction of 66 pmol/L (-65.8 (95% CI -78.1 to -53.6 pmol/L 
p<0.00001) for metformin use in an analysis of a more heterogeneous group of patients 
  
(including studies of specific groups of patients with hyperlipidaemia and polycystic ovarian 
syndrome) [8].  Our result is also similar to that of Liu et al (2014) [9], who found a reduction 
of  54 pmol/L in a meta-analysis, but included rosiglitazone as a control in the pooled 
estimate. The fact that our estimate is similar to these other meta-analyses suggests that the 
effect of metformin on B12 may not vary by patient population studied and thus separate 
guidance might not be required for different clinical populations. The concordance with the 
other meta-analysis also supports the reliability of our effect size.   Since our electronic 
searches were completed there have been 8 observational studies published that are relevant 
to our review [45-51]. All of these studies have supported a reduction in B12 status with 
metformin use, or higher than expected levels of deficiency in metformin using patients. Of 
note, Beulens et al. (2015) found both reduced vitamin B12 and holotranscobalamin in 
metformin users [51].  Therefore, inclusion of these articles would have been unlikely to 
change the overall results of our systematic review, although it is important to note that the 
study by de Groot-Kamphuis et al. (2013) found that metformin use was not associated with 
risk of neuropathy or anaemia [46].  Importantly, there have been no new intervention studies 
published to the authors’ knowledge since the end date of our searches so our meta-analysis 
estimate for intervention studies can be considered up to date.  
 
4.1 Limitations  
Strengths of this work include the fact that to the author’s knowledge, this is the first 
systematic review and meta-analysis to summarise all the research evidence for the 
association between metformin and vitamin B12 deficiency in patients with Type 2 Diabetes 
specifically. However, most of the studies in this review were conducted in outpatient clinics 
and not in primary care, which limits generalizability. The wide variation in study design, 
wide confidence intervals in some studies, lack of standardisation of assessment of vitamin 
  
B12 status and a small number of interventional trials makes clear conclusions difficult to 
elucidate. Usage of a random effects model due to the presence of heterogeneity made the 
estimate for the B12 reducing ability of metformin slightly larger, with wider confidence 
intervals.  Our meta-analysis only included trial measurements at ≤4 months, so may not be 
applicable for longer time scales. Effect sizes may differ by age group of trial participants 
(e.g. the lowering effect could theoretically be more profound in the elderly), but this could 
not be assessed in this analysis due to a lack of studies in different age groups.   
 
There were also other limitations in terms of study quality and design for the intervention 
studies, with Jadad score ≤ 3 in all but one study. Only one of the intervention studies 
(HOME study, data in two papers [37, 40] ) met the criteria for a double blind randomised 
placebo controlled trial.  This is likely to affect the accuracy of the meta-analysis estimate 
calculated. Most studies contained a small number of participants, leading to the HOME trial 
[37] receiving 55% of the weight in the meta-analysis. However, the sensitivity analysis 
showed that removal of this trial from the analysis did not greatly change the effect size.  We 
could not conduct funnel plots to assess bias (e.g. publication bias) as we only had four 
studies in the review, and funnel plots are known to be  less reliable for analyses based on a 
small number of trials, studying a small sample of individuals [52].    
 
Finally, due to lack of data secondary outcomes were not assessed as a part of this review but 
highlight a research gap warranting further study.  Also there was some suggestion in three 
studies that dose and duration of metformin could be significant factors in determining B12 
levels [34] [26, 53]. This also could not be assessed in more detail due to lack of studies 
reporting data for dose and duration.   
 
  
 
4.2 Implications for research and practice 
Our meta-analysis provides an assessment as to the effect size of the association between 
metformin and B12 status specifically in patients with Type 2 Diabetes, based on a meta-
analysis of short-term therapy (up to 4 months).  
 
Clinically, our results suggest that there is a clear need for evidence based guidelines and for 
examination of the implications for practice. The traditional treatment for B12 deficiency has 
been with parenteral therapy due to poor oral absorption. However, it is currently recognised 
that high dose oral B12 (1000 µcg) appears to rectify the levels in most patients [35] being as 
effective as parenteral therapy [54, 55]. Regular oral B12 or annual B12 injections have 
been recommended as safe ways to maintain levels in B12 deficient patients [55].  
Therefore effective treatments are available, but it is unclear what the vitamin B12 monitoring 
strategy should be for patients being prescribed metformin. The results of this systematic 
review and meta-analysis suggest that further large cohort studies and high quality longer 
term intervention studies assessing clinical endpoints of vitamin B12 deficiency are now 
required, in order that evidence based-guidelines can be produced for screening and 
treatment of vitamin B12 deficiency in metformin treated patients with type 2 Diabetes. 
 
In addition, this review suggests the need for a cost-benefit analysis, comparing a ‘watch and 
wait’ strategy of clinical case finding versus regular vitamin B12 status checks. This should 
consider the management of B12 status in screened vs. unscreened patients, and the effects of 
this upon usage of healthcare services e.g. falls in the elderly secondary to neurological 
damage.[56]   
5.0 CONCLUSION  
  
 
This review of patients with Type 2 Diabetes shows a reduction in B12 status by 57pmol/L 
after up to 4 months of metformin use, which based on European data for B12 status would be 
predicted to lead to frank deficiency in a significant proportion of patients. Our findings 
support that of a previously published meta-analyses of more heterogeneous populations of 
metformin users [8, 9]. A cost-benefit analysis is now required to fully investigate the most 
effective protocols for treating this widespread problem (e.g. watch and wait vs. clinical 
screening) and appropriate clinical guidelines produced. 
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TABLES AND FIGURES
  
Table 1 Characteristics of n=17 included cross sectional studies 
 
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
Adetunji 
(2009)[27] 
Mean/S
D 
59±14 
Range 
56-61 
520 
 
279 
 
 
²NS Mean/SD  
11±7 yrs 
0  
(units not 
specified) 
 
 
B12 levels (if 
Hb <11g/dl) 
BMI 
HbA1c 
MCV 
 
0 0 363±149 416±106 P = 0.31 
Al-Gadeer 
(2007)[28]  
NS 134 NS NS NS (units and 
reference 
range not  
specified) 
 
HCy       
(units and 
reference 
range not 
specified) 
NS NS NS NS NS 
Carpentier 
(1976)[18] 
Mean/S
D  
61.9±2.
3 yrs 
70 30 NS Mean/SE
M  
46.5±7.9 
mths 
5 
(<270 
pg/ml) 
 
None 
7% 12% 
 
Mean/SEM  
454.9±36.6 
Mean/SEM  
760.9±59.9 
751.6±118 
P<0.001 
P<0.005 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
Chen       
(2012)[19] 
65.5±10
.6 (Met) 
68.6±12
.1 (Non-
Met) 
202 
 
 
 
152 
 
 
 
1500±578 
(mg/d) 
 
8.5±5.4 
yrs 
0 
(<130 ng/l) 
 
 
HoloTC 
(>35 
pmol/l) 
MMA 
(<0.42 
μmol/l) 
Folate 
(2.1–20 
μg/l) 
Ferritin 
(15–300 
μg/l) 
Neuropath
y – 
Vibration 
perception 
threshold 
(<25V), s-
LANSS 
(<12), 
NTSS-6 
(<6) 
0 0 219±105.4 281.4±95.1 P < 0.001 
 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
Filioussi 
(2003)[29] 
61.8/7.8 
(M) 
63.1/7.2 
(F) 
Range 
42-87 
600 
 
574 
 
NS 11.8±3.6 
yrs 
54  
(<200 
pg/ml) 
 
B12 levels 
(<200 
pg/ml) 
9% 
 
 
9.4% NS NS 95% 
CI: 6.8–
11.6% 
Hermann 
(2004)[17] 
Mean 
61.5 
Range 
37-81 
84 53 
 
Mean 200 
(mg/d) 
2200 
Mean 
 
5.2 yrs 
4 
(<150 
pmol/l)       
B12     
(150–700 
pmol/l) 
Folate (6–
35 nmol/l) 
HCy (< 15 
μmol/l) 
MMA (< 
0.28 
μmol/l) 
HoloTC 
(37–171 
pmol/l) 
 
5% 8% 
 
 
 
 
289±137 395±162 P  < 0.0039 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
Jones      
(2012)[30] 
Mean 
63.5 
Range 
36-91 
127 
 
 
127 
 
NS 1-25 yrs 
 
32 
(<180  
pg/ml) 
 
None 25% 25% 
 
NS NS NS 
Kos         
(2012)[20] 
 
63±13 
Range 
20-93 
706  
297 
Mean 
(mg/d) 
1500 
NS 
 
NS 
 
(<220 
pg/ml)) 
BMI 
Osteoporo
sis 
Osteoopeni
a 
NS NS 496±282 637±352 P < 0.0001 
Obeid     
(2013)[21] 
67 
(control
) 
64(DM) 
Range 
52-82 
164 
(B12 
measure
d in 
118) 
 
 
49 
 
 
NS 
 
 
 
NS 
 
 
 
NS 
(pmol/l) 
 
(reference 
range not  
specified) 
 
 
 
 
 
RBC-B12 
(pmol/l) 
tHCy 
(μmol/l) 
MMA 
(nmol/l) 
HoloTC 
(pmol/l) 
SAM 
(nmol/l) 
NS 
 
 
 
 
NS Median 
(10th-90th 
percentiles)  
 
256            
(139 -373) 
 
 
 
Median 
(10th-90th 
percentiles)  
305        
(191-475) 
P < 0.006 
 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
SAH 
(nmol/l) 
Pierce      
(2012)[31] 
59±9.2 
 
235 235 Mean 
(mg/d) 
2050 
Mean 
 
5.2 yrs 
6 
 
(<157 
pg/ml) 
Complicati
ons of 
deficiency 
2.5% 2.5% NS NS NS 
Pflipsen  
(2009)[22] 
 
 
 
61.5±96 195 
 
 
133 
 
<1000 - 
≥2000 
(mg/d) 
NS 1 
 
(<100 
pg/ml) 
 
 
B12 levels 
(100-350 
pg/ml)  
elevated 
MMA ( 
>243 
nmol/l)  
 HCy 
(>11.9nnm
ol/) 
0.5% 0.75% 
 
425.99 
 
 
 
527.49 P < 0.012 
Pongchaide
cha  
(2004)[23] 
35-65 
yrs 
(range) 
152 
 
88 
 
NS ≥ 6 
months 
NS 
(pg/ml) 
(reference 
range not 
specified) 
HCy 
Folic acid 
NS NS 318±192.2 
 
434.3±300.
7 
P = 0.011 
 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
Qureshi  
(2011)[32] 
 
NS 
 
283 
 
283 
 
≥ 
2000mg/d 
≥ 4 yrs 23 
(<150 
pg/ml) 
Neuropath
y 
Folate 
33% 33% NS 
 
NS NS 
Reinstatler     
(2006)[24] 
63.4±0.
5 (Met) 
66.4±0.
5 (Non-
Met) 
8488 
 
575 
 
NS 5yrs 
(median) 
<1 to >10 
yr 
NS 
(<148 
pmol/l) 
B12 levels 
(<148-221 
pmol/l) – 
borderline 
deficiency 
2.2%        
(Non-Met) 
3.3%        
(Non-DM) 
5.8% 317.5 386.7 
 
P = 0.0116 
 
 
Sorich     
(2008)[33] 
 
Median/ 
Range 
73 (31-
86) 
60 
 
60 
 
500-
3000mg/d 
Median/ 
Range 
6.5 (2-26) 
8 
(<150 
pmol/l) 
 
 
Dose and 
duration 
of 
metformin 
Age, 
Calcium 
supplemen
t 
Proton 
Pump 
Inhibitors 
15% 15% Median/ 
Range 
245 (83-
807) 
 
³N/A 
 
P = 0.10 
 
Tal          81±7.2 1570 255 NS NS NS(<200 Age, 
Medicatio
15% 24% NS NS P < 0.001 
  
Study Age n 
General 
Study 
populat
ion 
n 
Metformin 
population 
Dose Duration ¹Primary 
Outcome; 
N for B12 
deficiency 
 
Secondary 
study 
outcomes² 
% 
Deficiency 
Prevalence 
Study 
population 
% 
Deficiency 
Prevalence 
Metformin 
population 
B12 level 
metformin 
 
B12 level 
non 
metformin 
 
P value or 
95% CI 
(2010)[25] 
 
 
 
 
(M)  
82±6.9 
(F) 
pg/ml) 
 
 
 
n,Mortalit
y 
 
Tomkin   
(1971)[26] 
Mean 
/SEM 
62.5±1.
66 
71 71 
 
1500-
2000 
mg/d 
4.2 yrs 3 
(<150 
pg/ml) 
 
Hb 
(g/100ml) 
B12 (pg/ml) 
4% 
 
4% NS NS P < 0.02 
All data are Mean±SD unless otherwise stated ¹Primary outcome, outcome of primary interest for the cross-sectional study ²Secondary outcomes, outcomes of secondary 
interest for the cross-sectional study N/A – not applicable. NS – not specified Met=Metformin Non-Met=Non Metformin, DM=diabetes mellitus. Holotranscobalamin 
(HoloTC),   Methylmalonic acid (MMA)  Methylation markers: S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH),  NTSS-6 = Neuropathy Total Symptom 
Score-6 questionnaire , s-LANSS = the Self-administered Leeds Assessment of Neuropathic Symptoms and Signs questionnaire, Haemoglobin (Hb), Glycosylated 
Haemoglobin (HbA1c)
  
 
Table 2 Characteristics of n=4 included cohort and case-control studies  
 
Study Setting Participants N  and 
Exclusion 
criteria 
Allocation Primary 
study 
outcome¹ 
Secondar
y study 
outcomes² 
Review 
outcome 
(B12 
levels)³ 
% Incidence 
B12 deficiency 
or Odds Ratio 
P 
value 
Comments 
Long         
(2012)[36
] 
US 
Medical 
Centre 
 
Electronic 
Medical 
Records 
 
Study 
period; not 
specified 
 
Diabetics 
(Type 2) 
 
589 (96%) 
men/25 (4%) 
women 
 
Age 
(Mean/SD) 
65.08/9.23 
 
Not specified 
how long 
patients had 
been on 
metformin 
614 
Exclusions-  
Over 60 years, 
Vegetarian, 
Pernicious 
anaemia, 
Pancreatic 
insufficiency, 
Gastrectomy, 
Bowel 
resection, 
Calcium 
supplementation
, H2 blockers in 
the last 3 
months 
 
Retrospective 
146 (24%)  
metformin 
123 (20%)  
metformin + 
PPI 
129 (21%) PPI 
216 (35%) 
control 
 
B12 levels 
(<300 pg/ml) 
 
 
Effect of 
Proton 
Pump 
Inhibitors 
(PPI’s) 
 
B12 levels 
(<300 
pg/ml) 
 
32 (21.91%)  
metformin 
 
42 (34.15%)  
metformin + 
PPI 
 
33 (25.58%) PPI 
 
48 (22%) 
control. 
P = 
0.9454 
metfor
min 
 
 
 
P = 
0.0009
6 
metfor
min +  
PPI 
 
 
 
P = 
0.9454 
PPI 
 
No statistically 
significant 
difference 
between 
control group 
and those on 
metformin or 
PPI alone 
A statistically 
significant 
difference 
between 
control group 
and those on 
metformin + 
PPI 
 
 
 
  
Study Setting Participants N  and 
Exclusion 
criteria 
Allocation Primary 
study 
outcome¹ 
Secondar
y study 
outcomes² 
Review 
outcome 
(B12 
levels)³ 
% Incidence 
B12 deficiency 
or Odds Ratio 
P 
value 
Comments 
Hermann   
(2004)[17
] 
Sweden 
 
 
Diabetic 
outpatient 
clinic 
 
 
Study 
period; 
May 2002 
-May 2003 
 
Type 2 
Diabetes 
 
 
50 (60%) 
men/34 (40%) 
women 
 
 
Age (Mean) 
61.5 
 
Metformin for 
at least 1 year 
84 
 
Exclusions – 
 
metformin 
treatment < 1 
year,  
elevated 
creatinine,  
B12 deficiency, 
pregnancy, 
thyroid/ 
inflammatory 
bowel disease, 
acute diseases, 
cancer, 
psoriasis,  
relevant 
medication 
Retrospective 
 
Non-
randomised. 
 
 
53 (63%) 
metformin 
31 (37%) non- 
metformin 
diabetics 
(controls) 
B12 status  
(vitamin B12) 
 
 
HoloTC, 
 
 
Hcy   
 
 
MMA 
vitamin B12      
(150–700 
pmol/l) 
 
 
Folate  
(6–35 
nmol/l) 
 
 
Hcy (< 15 
μmol/l) 
 
 
MMA (< 
0.28 
μmol/l) 
 
HoloTC 
(37–171 
pmol/l) 
B12 levels 
(vitamin 
B12) 
(<150 
pmol/l) 
 
289±137 
(Met) 
395±162 
(Non-
Met) 
4 (8%)  
prevalence of 
B12 deficiency 
in patients with 
diabetes on 
metformin 
 
 
(26.7% lower 
vitamin B12 
levels in 
exposed group 
compared to 
non-exposed) 
B12 
P < 
0.0039 
 
 
Holo-
TC 
P = 
0.065 
 
 
Hcy 
P= 
0.0484 
Vitamin B12 (p 
< 0.01),  
Hcy (p < 0.05)  
HoloTC (p < 
0.05)  
Were all 
statistically 
significantly 
lower in the 
metformin 
group. 
 
 
4 (8%) had 
vitamin B12 
and 8 (16%)  
(p <0.05) had 
HoloTC levels 
below the 
reference 
ranges 
 
 
 
 
 
 
  
Study Setting Participants N  and 
Exclusion 
criteria 
Allocation Primary 
study 
outcome¹ 
Secondar
y study 
outcomes² 
Review 
outcome 
(B12 
levels)³ 
% Incidence 
B12 deficiency 
or Odds Ratio 
P 
value 
Comments 
Ting          
(2006)[34
] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hong 
Kong 
 
Pathology 
laboratory 
database 
 
Study 
period;  
Jan 2003 -  
Nov 2005 
 
Type 2 DM 
57 (37%) 
men/98(63%)
women (cases) 
127(41%) 
men/183(59%) 
women 
(controls) 
Age: 
72.5±9.3(cases
) vs.71.4±11.2 
(controls) 
Median 
duration 
metformin 
(yrs); 
4(cases)/2 
(controls) 
Dosage; 2g 
(cases)/1.4g 
(controls) 
3987 
Exclusions –  
 
Diabetics not on 
metformin,  
 
Less than 1 year 
of computerised 
medical records,  
 
Pernicious 
anaemia, 
 
Pancreatic 
exocrine 
insufficiency, 
 
Gastrectomy/ 
small bowel 
resection,  
 
Vitamin B12 
supplementation 
within 3 months 
prior to study 
Nested 
3632 (91%) 
diabetics on 
metformin with 
no B12 
deficiency 
355 (9%) 
diabetics on 
metformin with 
B12 deficiency 
After 
exclusions; 155 
cases/310 
matched 
controls 
 
B12 levels  
(<150 
pmol/l) 
(203.3 
pg/ml) 
 
 
HbA1c B12 levels  
(<150 
pmol/l) 
(203.3 
pg/ml) 
 
Mean; 
148.6 
(cases)/46
6.1 
(controls) 
 
Metformi
n related 
B12 
deficiency 
after 3 
years 
 
8.91 (95% 
CI, 0.91-73.9) 
 
 
 
- 
 
 
 
 
 
 
2.37 (95% 
CI, 1.60-3.52) 
P = 
0.06 
 
 
 
P<0.00
1 
 
 
P 
<0.001 
 
Cases more 
likely to be 
vegetarians(P 
= 0.04) 
Prevalence 
2.6%(cases)v.s
.0.3% 
(controls) 
Significant 
increased risk 
with dose and 
duration    (P 
<0.001). Each 
1g dose leads 
to over double 
the risk of B12 
deficiency 
 
 
 
 
 
  
Study Setting Participants N  and 
Exclusion 
criteria 
Allocation Primary 
study 
outcome¹ 
Secondar
y study 
outcomes² 
Review 
outcome 
(B12 
levels)³ 
% Incidence 
B12 deficiency 
or Odds Ratio 
P 
value 
Comments 
Wile          
(2010)[53
] 
Canada 
 
NM Clinic 
 
Study 
period; 
Dec 2002 -  
May 2007 
 
Diabetics 
(Type 2) with 
Neuropathy 
 
35 (59%) 
men/24 (41%) 
women (cases) 
34 (54%) 
men/29 (46%) 
women 
(controls) 
 
Age 
(Mean/SD) 
66.6(11.9)/ 
(cases) 
64.8(12.0)/ 
(controls) 
Metformin for 
at least 6 
months 
122 
Exclusions –  
 
Non-DM 
potential 
causes for 
peripheral 
neuropathy, 
 
Cbl deficiency, 
 
Discontinued 
metformin or 
had received <6 
months of 
metformin, 
 
Impaired 
glucose 
tolerance,  
 
Juvenile 
Diabetes onset,  
 
Insulin, 
 
Refused  testing 
Prospective 
 
59 (48%) 
metformin 
63 (52%) non 
metformin 
diabetics 
(matched 
controls) 
Vitamin B12      
 
 (210pmol/l)  
 
(285 pg/ml) 
 
Vitamin 
B12      
(pmol/l) 
 
 
Hcy 
(μmol/l) 
 
 
MMA 
(μmol/l) 
 
Neuropathy 
(nerve 
conduction 
studies/ 
TCSS/NIS) 
Vitamin 
B12      
(210 
pmol/l) 
(285 
pg/ml) 
 
Median 
levels; 
231 
(cases)/48
6 
(controls) 
Deficienc
y;  
18(31%) 
(cases) 
vs. 2 (3%) 
(controls) 
Cumulati
ve dose: 
inversely 
correlated 
with B12 
levels 
NS P<0.00
1 
 
 
 
P<0.00
1 
 
 
 
P = 
0.001 
Neuropathy:M
edian TCSS 
and NIS score 
higher in cases 
(p <0.001), 
and correlated 
to cumulative 
dose (p 
<0.001). 
 Nerve 
conduction 
studies were 
not 
significantly 
correlated. 
  
Study Setting Participants N  and 
Exclusion 
criteria 
Allocation Primary 
study 
outcome¹ 
Secondar
y study 
outcomes² 
Review 
outcome 
(B12 
levels)³ 
% Incidence 
B12 deficiency 
or Odds Ratio 
P 
value 
Comments 
 
¹Primary outcome, outcome of primary interest for the studies, ²Secondary outcomes, outcomes of secondary interest for the studies, ³Review outcome, outcome relevant for 
inclusion within the systematic review – serum B12 levels,  NS=not stated, Hcy=Homocysteine, HoloTC= Holotranscobalamin II,   MMA=Methylmalonic acid TCSS=, 
Toronto Clinical Scoring System, NIS=Neuropathy Impairment Score, NM=neuromuscular
  
Table 3 Characteristics of n=5 included clinical trials  
 
Study 
 
 
Setting/ 
Study 
period 
Participants   
Male (%)/ 
Female (%) 
Age  Inclusion/ 
Exclusions 
Intervention Study design Primary 
study 
outcome 
Secondar
y study 
outcomes 
Statistical 
Analysis 
Cases 
Statistical 
Analysis 
Controls 
Jadad/ 
GRAD
E 
Comment 
Bauman 
2000[39] 
 
 
US             
4 
months 
 
21              
21(100%) 
 
 
48.6 
±10.1 
cases 
54 
±4.9  
control 
 
I(30-60 yrs)/E2 850mg 2 or 3 
times daily 
Controlled  
Not 
randomised 
 
 
B12 
levels  
(<220 
pg/ml) 
 
 
 
Hydroge
n breath 
test for 
bacterial 
overgrow
th 
Baseline 
400±119 
3 Months   
282 ± 24 
4 months   
277 ± 22 
Baseline 
335±120 
 
3 months 
364±51 
4 months 
375±90 
 
0 
2C 
 
 
 
Statistical 
significant 
difference 
at 3 
months (p 
<0.001), 3 
to 4 
months (p 
<0.005) in 
cases 
 
Leung       
2010[41] 
Canada      
3 
months 
 
20       
                    
10 (50%)/ 
10 (50%) 
NS 
 
 
 
 
 
 
 
I(67-91 yrs) 
E (NS) 
 
NS Controlled 
Not 
Randomised 
 
Vitamin 
B12 
levels  
HbA1c 
(%) 
 
MMA 
(pm/l) 
Baseline    
400 
3 months   
290     
(p=0.04) 
Baseline 
465 
 
3 months   
439   
(p=0.75) 
0 
2C 
 
 
Reduction 
in levels 
after 3 
months in 
cases 
(24%) 
  
Study 
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Sahin        
2007[38] 
 
 
 
 
Turkey      
6 weeks 
 
165                         
66 (40%) 
/ 99 (60%) 
 
 
NS 165      
I(36-82 yrs)/ 
E3 
850mg 3 
times daily 
or placebo 
RCT 
 
B12 
levels       
(pmol/l) 
 
Hcy 
(µmol/l) 
 
Folate 
(nmol/l) 
Baseline 
319.3±14
9.6 
6 weeks 
290.22±1
40.5(p=0.
119) 
Baseline 
265.89±398 
 
6 weeks 
262.14±44.
4 (p=0.631) 
0/1 
2B/2C 
 
 
No 
statistical 
difference 
between 
cases and 
controls 
De Jager    
2010[40] 
Holland 
4.3 
years 
 
390 NS I(30-80yrs)  /E 
(NS) 
Insulin     
850mg od 
Multicentred
DBRPCT 
B12 
levels  
(<150 
pmol/l) 
 
 
 
B12 levels  
(<150-
220 
pmol/l) 
Folate 
(nmol/l) 
Hcy 
(µmol/l) 
Baseline 
to   4.3 
yrs 
89.8pmol/
l drop 
(−19% 
change) 
(95% CI 
−22% to 
−15%) 
Baseline to 
4.3 yrs 
0.2pmol/l 
drop (0% 
change) 
(95% CI 
−3% to 
4%) 
5 
1A 
 
 
Reduction 
in levels  
by 19%   
(95% CI 
−24% to 
−14%)  
(P<0.001) 
Wulffele    
2003[37] 
 
 
 
 
 
 
 
Holland
4 
 
390 NS I(30-80 yrs) 
/E (NS) 
Metformin     
850mg once 
per day 
Multicentred
DBRPCT 
B12 
levels  
(<180 
pmol/l) 
B12 levels  
(<180-
700 
pmol/l) 
Folate 
(nmol/l) 
HCy 
Baseline 
to   16 
wks 
47.4pmol/
l drop 
(−16% 
change) 
(95% CI 
Baseline to 
16 wks 
4.4pmol/l 
drop (-2% 
(95% CI 
−6% to 
2%) 
5 
1A 
 
Reduction 
in levels 
(14%)  
(95% CI 
−4.2% to 
−24%) 
(p<0.001)
) 
  
Study 
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 (µmol/l) −12% to 
−19%) 
 
All data are mean±SD unless otherwise stated. ¹NS – Not Specified. ² Exclusions – history of alcoholism /drug abuse, psychiatric/liver/stomach/bowel/cardiopulmonary 
disease, chronic renal failure, pernicious anaemia, pre-existing vitamin B12 deficiency, bowel surgery, acid-based disturbance, or cancer, relevant medication 
(antibiotics/gastric motility drugs.³ Exclusions - smoking, cardiac arrhythmia, CCF, stroke, chronic renal disease, microalbuminuria, dyslipidemia, relevant medication, 
severe illness. 416 week interim result from the same study as deJager (2010)[40] 
 
 
 
  
Figure Captions: 
 
 
 
Figure 1 Study flow diagram illustrating the results of the search and the process of screening and the selection of the 
studies for inclusion in the review.  Legend: For the purposes of this flow chart Hermann et al (2004) is classified under 
cross sectional studies. 
 
 
  
 
 
Figure 2 The effect of metformin usage on serum B12 concentration (pmol/L), with fixed-effects weighted mean 
difference used to compare vitamin B12 levels between studies. Legend: Experimental=Metformin, Control=Placebo 
 
 
 
